Enveric Biosciences

Psychedelic medicine developer

Enveric Biosciences is an active, development-stage biotechnology company developing small-molecule neuroplastogens for neuropsychiatric disorders. Its pipeline includes EB-003, in preclinical IND-enabling development, and the EVM401 discovery-stage compound series. The company is headquartered in Cambridge, Massachusetts; the supplied information does not specify ownership changes. Its candidates are investigational and are not approved or available to buy.

Website

enveric.com

Enveric Biosciences catalog

All products · Psychedelic medicine pipeline

Shop the Enveric Biosciences catalog

2 items across 1 shelf

Psychedelic medicine pipeline2 items

• EB-003 – Novel neuroplastogen designed to engage 5-HT2A and 5-HT1B receptorsInvestigational
• EVM401 – Novel phenylalkylamine and indolethylamine seriesInvestigational